Skip to main content
Premium Trial:

Request an Annual Quote

Roche's Bid to Acquire Illumina Topped Readers' Interest in 2012

NEW YORK (GenomeWeb News) – Roche's bid to acquire Illumina, which was ultimately unsuccessful in the early part of 2012, topped our list of most-viewed articles on GenomeWeb Daily News for the year.

A series of articles on Roche's pursuit and Illumina's efforts to fend off the hostile takeover bid claimed six of the top 10 most-viewed articles on GWDN for 2012:

1) Illumina Creates Poison Pill in Response to Roche Bid
2) Roche Announces $5.7 Billion Hostile Takeover Bid for Illumina
3) Shareholders File Lawsuit Against Illumina
4) Roche Names Proposed Board Nominees for Illumina
5) Shares of Sequencing Instrument Makers Fall as Oxford Nanopore Unveils Platforms
6) Roche Claims 'Other Options' If Illumina Deal Fails
7) Roche Extends Tender Offer for Illumina
8) Illumina Confirms Unsolicited Bid for Complete Genomics
9) Promega Awarded $52M in Suit Against Life Technologies
10) Complete Genomics, BGI Agree to $117.6M Merger

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.